Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725322 · ClinicalTrials.gov registry record · NA
Subcutaneous Botulinum Toxin for Cutaneous Allodynia
A NA study of Pain, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT00725322: Completed NA study of Pain, sponsored by Stanford University.
NCT00725322 is a NA study of Pain that has completed, run by Stanford University. The registered enrollment target is 84 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725322, a NA study of Pain, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. The investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).
Primary Outcome
Participants made daily NRS reports via Palm Pilot, and "failure" was defined as (Pre-injection baseline NRS) - (Mean NRS for any 3 preceding days) ≤ 0; or 9 months
Conditions Studied
Interventions
- DRUG Botulinum Toxin A
- DRUG Placebo - Saline
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-03 |
| Phase | NA |
What the finished NCT00725322 record still lists
NCT00725322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Botulinum Toxin A is the first listed.
NCT00725322 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00725322 about?
NCT00725322 is a clinical study titled "Subcutaneous Botulinum Toxin for Cutaneous Allodynia". Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients w...
What is the current status of trial NCT00725322?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2007-12. Estimated completion is 2013-03.
What conditions does trial NCT00725322 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT00725322?
The interventions under investigation include: Botulinum Toxin A (DRUG), Placebo - Saline (DRUG).
Who is sponsoring clinical trial NCT00725322?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00725322 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00725322's enrollment target sits among peer trials
84 188th of 374 higher than 184 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Pain With Dementia
RECRUITING · NA
-
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia